Duration
36 months
Cost
Free to Patients
Phase
Phase III
Closes
Jan 2026
Evaluating olaparib as maintenance therapy for BRCA1/2 mutated HER2-negative metastatic breast cancer.
Patient Advocacy Endorsed
This trial has been reviewed and endorsed by Breast Cancer Research Foundation. PAG endorsement means patient advocates have evaluated the trial design, risk-benefit profile, and patient-friendliness of this study.
Only 12 spots remaining
Apply soon to secure your place.
Check your eligibility in under 2 minutes. No commitment required β a coordinator will guide you through next steps.
Check My Eligibility βFree to apply Β· No medical records needed to start
Trial Summary
Merck Sharp & Dohme
Evaluating whether adding pembrolizumab to chemotherapy improves outcomes in HER2-negative breast cancer.
NCT05723489